GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer Study

GSK plc GSK announced headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy, for primary advanced or recurrent endometrial cancer. 

Also Read: Competition and Optimism: GSK's CEO Walmsley Foresees Growth Despite Competition In RSV Vaccine Market.

The trial, which evaluated this combination against placebo plus chemotherapy followed by placebo, met its primary endpoint of progression-free survival (PFS), with a statistically significant and clinically meaningful benefit observed in both the overall patient population and in a subpopulation of patients with mismatch repair proficient/microsatellite stable (MMRp/MSS) tumors. 

OS data is immature and will continue to be followed. 

The safety profile of dostarlimab plus carboplatin and paclitaxel, followed by dostarlimab plus niraparib, was generally consistent with the known safety profiles of the individual agents. 

Endometrial cancer is the most common gynecologic cancer in developed countries, with approximately 417,000 new cases reported each year worldwide, and incidence rates are expected to rise by almost 40% between 2020 and 2040.

GSK says MMRp/MSS primary advanced or recurrent endometrial cancer has limited treatment options beyond chemotherapy alone.

Last month, GSK announced headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase 3 trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. 

Price Action: GSK shares are up 1.18% at $36.31 on the last check Monday.

Photo via Company